VULGARIS
Glenmark, Cosmo get MHRA nod for acne treatment medication
Glenmark Pharmaceuticals and Cosmo Pharmaceuticals have received MHRA approval to market Winlevi, a topical acne treatment for patients aged 12 and older in the UK. Glenmark licensed the product from Cosmo for distribution in Europe and South Africa, aiming to improve the quality of life for those suffering from acne, which affects a significant portion of the global population.
Your nose may be warning you about serious health issues: Vital nasal signals you shouldn't miss
The nose provides valuable health cues. Persistent congestion, unusual smells, or changes in appearance could signal health issues. Acne vulgaris and rosacea can affect the nose. Sarcoidosis may cause bluish rashes, and trigeminal trophic syndrome can numb the nose. Monitoring these signs can aid early diagnosis and treatment of underlying conditions.
Biocon Biologics grants Sandoz exclusive rights to market biosimilar adalimumab in Japan
Adalimumab BS for subcutaneous injection is indicated for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.
Why is retinol considered the antidote to ageing?
Retinol is a catch-all term often used to describe vitamin A and other retinoids (a group of fat-soluble compounds consisting of retinol and other structurally related substances).
Love pulses? Here's five interesting trivia about this superfood
According to researchers, pulses may be the key to curing world hunger.
Dr Reddy's completes clinical studies of its proposed rituximab biosimilar candidate
Following completion of the full set of clinical studies, Dr Reddy's said it will now prepare to file in the US, European Union and other regions for approval of 'DRL_RI'.
- Go To Page 1
Does Sun Pharma's specialty portfolio hold key to its performance?
According to the FY 2022 annual report of Sun Pharma, it is ranked number 1 in terms of prescriptions with an 8.34% market share in India. The company has 32 brands among India’s top 300 brands. The company offers drugs in various therapeutic segments such as neuropsychiatry, cardiology, diabetes, gastrointestinal, pain/analgesics, gynaecology, ophthalmology, urology, dermatology, respiratory and anti-infectives.
Sun Pharma expands tie-up with Cassiopea for acne cream to six countries
As per the tie-up, the company will receive from Cassiopea the exclusive right to develop and commercialise WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia, Sun Pharma said in a statement.
Sun Pharma gets exclusive right to commercialise Winlevi acne cream in US, Canada
Sun Pharma, North America CEO Abhay Gandhi said the expiration of the applicable waiting period under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) clears the path for making Winlevi available to patients and healthcare providers in the US and Canada.
Alembic Pharma gets USFDA nod for generic acne treatment gel
Alembic Pharmaceuticals on Friday said its joint venture has received nod from the US health regulator for generic Adapalene gel used for treatment of acne.
Queens of the Stone Age's 1998 debut album 'Villains' will make you dance
In the middle of all the fairy lights and felicitations jumps out this devil’s whiplash of a guitar riff.
Sun Pharma surges after USFDA approves drug application for acne treatment
Sun Pharma surged over 3% in trade today after the drug major received approval from the US health regulator for its new drug.
Sun Pharma gets USFDA approval for acne drug
Sun Pharmaceutical Industries today said it has received approval from the US health regulator for its new drug application for acne treatment medicine--XiminoTM extended-release capsules.
Sun Pharma to buy US-based DUSA Pharmaceuticals for $230 million
Under the terms of agreement, a 100% subsidiary of Sun Pharma will commence a tender offer for all outstanding common stock of DUSA at a price of $8 per share.
Sun Pharma to acquire US dermatology company DUSA Pharma
Sun Pharma is to acquire US-based DUSA Pharmaceuticals, Inc, a dermatology company focused on developing and marketing its Levulan (aminolevulinic acid HCl) photodynamic therapy platform.
Load More
